Nachrichten zur MacroGenics Inc. Aktie

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Jan. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and…

MacroGenics Announces MGD019 Publication in Cell Reports Medicine

PD-1 × CTLA-4 Bispecific DART® molecule is preliminarily well-tolerated in dose escalation clinical study PD-1 × CTLA-4 Bispecific DART® molecule…

MacroGenics, Janssen Biotech in licensing pact for DART molecule

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule

ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on…

Why MacroGenics Stock Soared Then Sank Today

There were different reactions to the companys first FDA approval....…

The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut

Heres a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week…

Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

SHANGHAI and SAN FRANCISCO, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limiteds (NASDAQ: ZLAB; HKEX: 9688) partner…

MACROGENICS INC: 8-K Report

8-K...…

MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

ROCKVILLE, MD, Dec. 16, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and…

MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting

ROCKVILLE, MD, Dec. 07, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused…

MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting

ROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused…

MacroGenics (MGNX) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MACROGENICS INC: 8-K Report

8-K...…

MacroGenics secures $25M milestone payment from Incyte

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte

ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused…

MacroGenics: Q4 PDUFA Target Action Date, 2021 Expected Revenue Growth Of 116%, And $281M In Cash Make It A Buy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q3 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics (MGNX) Q3 2020 Earnings Call Transcript

MGNX earnings call for the period ending September 30, 2020....…

MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 28.26% and 77.63%, respectively, for the quarter ended September 2020. Do the…

MACROGENICS INC: 10-Q Report

10-Q...…

MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020

ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on…

MACROGENICS INC: 8-K Report

8-K...…

MacroGenics reports that AML patients benefit from flotetuzumab immunotherapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics Announces Flotetuzumab Publication in Blood Advances

— Role of TP53 abnormalities in immunotherapy response in AML highlighted — Role of TP53 abnormalities in immunotherapy response in…

MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics

ROCKVILLE, MD, Sept. 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on…

MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood

ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on…

MacroGenics announces development milestone achieved in retifanlimab collaboration with Incyte

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte

ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused…

MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020

ROCKVILLE, MD, Sept. 20, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on…

MacroGenics (MGNX) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused…

MacroGenics (MGNX) Q2 2020 Earnings Call Transcript

MGNX earnings call for the period ending June 30, 2020....…

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -6.82% and 42.78%, respectively, for the quarter ended June 2020. Do the…

MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results

Conference call scheduled for today at 4:30 p.m. ET. Conference call scheduled for today at 4:30 p.m. ET....…

MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call

Rockville, MD, July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused…

MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer

Rockville, MD, July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused…

The Play On MacroGenics

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MACROGENICS INC: 8-K Report

8-K...…

MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer

Rockville, MD, June 16, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused…

Why MacroGenics Is Moving Today

MacroGenics Inc (NASDAQ: MGNX) shares are moving on Friday. The company announced the FDA has granted Orphan Drug Designation to Margetuximab in…

Thinking about trading options or stock in Novavax, Southwest Airlines, Las Vegas Sands, Carnival Corp, or MacroGenics?

NEW YORK , June 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for…

MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer

Rockville, MD, June 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused…

MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia

Rockville, MD, June 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused…